Patients prescribed Ganfort, or Ganfort PF (bimatoprost/timolol) and Lumigan, or Lumigan PF (bimatoprost) eye drops can be enrolled in AbbVie’s free two-year programme, which provides them with ongoing support through their glaucoma journey.
In addition to timely reminders to use their medication, enrolled patients receive a series of messages on their device via SMS or the MedAdvisor app, arriving at pre-determined intervals: 12 messages in year one and nine messages in year two.
As of August 2024, over 8,000 patients were enrolled on the AbbVie adherence programmes. Patients enrolled in the programme have been dispensed 7.31 additional scripts versus patients not enrolled on the programme. AbbVie has reported a 69% incremental uplift on persistence to treatment for new patients after 24 months on the adherence programme.
